Syndax Pharmaceuticals, Inc. (SNDX) Stock Grade

About Syndax Pharmaceuticals, Inc.'s fundamentals

Syndax Pharmaceuticals is a biotechnology company with a market capitalization of $1.6 billion that reported dramatic revenue growth of 627.8% year-over-year, indicating rapidly expanding commercial operations. However, the company is currently unprofitable, with a net margin of -165.6% and a reported net loss in its latest annual statement, meaning expenses significantly exceed revenues. The company does not pay a dividend and, given its loss-making status, traditional valuation metrics like P/E ratio and return on equity are not applicable.